Ekso bionics holdings, inc. (EKSO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Mar'13Dec'12
Operating activities:
Net loss

-12,132

-26,992

-29,122

-23,470

-19,590

-33,769

-11,887

-

-15,042

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization

690

1,515

1,748

1,855

933

745

469

-

342

Provision for excess and obsolete inventories

66

191

73

30

34

-36

-8

-

20

Changes in allowance for doubtful accounts

52

-50

105

14

57

-

-

-

-

Finance cost attributable to issuance of warrants

1,096

0

-

-

-

-

-

-

-

(Gain) loss on revaluation of warrant liabilities

6,376

1,063

3,909

4,286

2,505

-16,485

186

-

-

Gain on change in fair value of warrant liabilities

-

-

-

-

-

0

-

-

-17

Interest income added to note receivable from stockholder

-

-

-

-

-

-3

0

-

4

Change in fair value of contingent consideration liability

-

-

-

-

-

0

-

-

-

Fair value of warrant accounted for as a reduction of revenue

-

-

-

-

-

-

-

-

58

Adjustment to record convertible note at fair value

-

-

-

-

-

-

-799

-

-174

Stock-based compensation expense

2,255

2,868

2,414

3,121

1,731

1,143

391

-

333

Loss on disposal of property and equipment

0

-126

0

-

-

-

-

-

-20

Amortization of debt discount and accretion of final payment fee

92

152

-

-

-

-

-

-

-

Amortization of deferred rent

-

-

-

36

37

-

-

-

-

Amortization of notes payable offering costs

-

-

-

-

-

-

21

-

8

Amortization of debt discount and accretion of final payment fee

-

-

179

0

0

20

231

-

43

Amortization of deferred rent

-

-

-

-

-

-36

-36

-

157

Amortization of debt discounts

-

-

-

0

0

208

169

-

121

Finance cost attributable to issuance of warrants

-

-

-

0

487

0

0

-

-

Change in fair value of contingent liabilities

28

35

213

196

0

-

-

-

-

Common stock contribution to 401(k) plan

142

212

509

0

0

-

-

-

-

Loss on modification of warrants

-257

0

-

-

-

-

-

-

-

Gain (Loss) On Repurchase Of Warrants

-

-

-1,067

0

0

-

-

-

-

Unrealized loss on foreign currency transactions

-133

-381

500

-135

0

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

1,599

850

1,085

-140

577

1,000

-239

-

397

Inventories

-893

1,655

2,096

541

200

-354

102

-

829

Prepaid expenses, operating lease right-of-use assets, and other assets current and noncurrent

-369

-1,046

862

60

91

36

87

-

5

Deferred costs of revenue

-

-

-

-4,590

1,022

1,995

442

-

1,130

Accounts payable

-1,231

752

77

-818

1,738

-716

-231

-

809

Accrued and lease liabilities

-1,135

559

105

1,468

-493

944

433

-

74

Deferred revenues

684

678

-

-

-

-

-

-

-

Deferred revenues

-

-

284

-6,943

1,266

2,679

1,164

-

2,602

Net loss for the period

-

-

-

-

-

-

-

-12

-

Increase (Decrease) in Accounts Payable and Accrued Liabilities

-

-

-

-

-

-

-

0

-

Net cash used in operating activities

-15,772

-22,165

-31,226

-24,997

-18,269

-

-

-11

-

Net cash used in operating activities

-

-

-

-

-

-15,007

-9,063

-

-12,663

Investing activities:
Acquisition of property and equipment

60

131

456

1,096

1,492

1,487

379

-

830

Net cash used in investing activities

-60

-131

-456

-1,096

-1,492

-

-

-

-

Financing activities:
Fees paid related to 2015 issuance of convertible preferred stock

-

-

-

173

0

0

-

-

-

Proceeds from issuance of common stock and warrants, net

21,188

4,446

42,463

14,694

0

21,961

0

27

0

Security deposits

-

-

-

-

-

-

-

-

10

Note receivable from stockholder

-

-

-

-

-

-

-

-

45

Net cash used in investing activities

-

-

-

-

-

-1,487

-379

-

-865

Proceeds from issuance of 2012 Series B convertible bridge notes, net

-

-

-

-

-

-

2,000

-

3,311

Proceeds from issuance of 2013 Series B convertible bridge notes, net

-

-

-

-

-

-

4,929

-

0

Proceeds from issuance of notes payable and warrants, net of issuance costs

-

-

-

-

-

-

-

-

3,500

Principal payments on note payable

2,377

2,174

54

79

60

2,596

1,829

-

610

Payment for private placement offering

-

-

-

-

-

-

948

-

0

Proceeds from issuance of convertible preferred stock and warrants, net

-

-

-

0

13,906

0

4,152

-

8,476

Proceeds from exercise of stock options

228

1

46

110

225

102

205

-

31

Proceeds from exercise of common stock warrants

-

-

113

1,825

53

21,412

0

-

0

Proceeds from issuance of long-term debt, net of financing costs

-

-

-

6,930

0

0

-

-

-

Proceeds from Contributions from Affiliates

-

-

-

-

-

-

-

5

-

Net cash (used in) provided by financing activities

19,039

2,273

42,568

23,307

14,124

-

-

32

-

Effect of exchange rate changes on cash

10

-135

-

-

-

-

-

-

-

Net increase (decrease) in cash

3,217

-20,158

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

40,879

8,509

-

14,708

Effect of exchange rate changes on cash

-

-

81

80

-1

0

-

-

-

Net increase (decrease) in cash

-

-

10,967

-2,706

-5,638

24,385

-933

20

1,180

Supplemental disclosure of cash flow activities
Cash paid for interest

23

18

20

33

5

-

-

-

-

Cash paid for income taxes

309

457

429

16

12

138

633

-

0

Cash paid for income taxes

-

-

-

-

-

38

25

-

387

Supplemental disclosure of non-cash activities
Initial recognition of operating lease right-of-use assets

1,454

-

-

-

-

-

-

-

-

Initial recognition of operating lease liabilities

1,498

-

-

-

-

-

-

-

-

Change in deferred rent associated with ASC 842

44

-

-

-

-

-

-

-

-

Transfer of inventory to equipment

-

-

554

11

0

0

-

-

-

Transfer of inventory to property and equipment

-77

1,118

-

-

-

-

-

-

-

Share issuance for common stock contribution to 401(k) plan

191

508

0

-

-

-

-

-

-

Issuance of Series A preferred stock warrants

-

-

-

0

11,700

0

0

-

-

Preferred deemed dividend to common shareholders in connection with anti-dilution feature associated with issuance of Series A preferred warrants

-

-

-

10,345

4,655

0

0

-

-

Share issuance in lieu of cash compensation

919

291

0

-

-

-

5

-

355

Share issuance for vesting of restricted stock

63

1

0

-

-

-

-

-

-

Equipois supply earn-out

-

-

189

0

0

-

-

-

-

Equipois sales earn-out

22

28

47

0

0

-

-

-

-

Equipois supply earn-out

-

-

189

-

-

-

-

-

-

April 2017 warrant issuance

-

-

3,301

0

0

-

-

-

-

Repurchase of April 2017 warrants and share issuance

-

-

2,245

0

0

-

-

-

-

Cumulative retrospective adjustment to retained earnings for ASU 2016-09 adoption

-

-

171

0

0

-

-

-

-

Conversion of preferred stock warrants to common stock warrants

-

-

-

-

-

282

0

-

0

Reclassification of warrant liability to equity upon exercise of warrants

-

-

62

1,363

0

27,099

0

-

0

Conversion of convertible notes into Series B convertible preferred stock

-

-

-

-

-

-

6,490

-

0

Common stock warrants issued in connection with Series B convertible preferred stock offering

-

-

-

-

-

-

169

-

0

Conversion of bridge loan to common stock

-

-

-

-

-

5,082

0

-

0

Acquisition of property and equipment with note payable

-

-

-

-

-

-

-

-

200

Acquisition of property and equipment with capital lease

-

-

-

0

166

-

-

-

23

Transfer of property and equipment from inventory

-

-

-

-

-

-

-

-

467

Conversion of bridge loan to common stock

-

-

-

-

-

-

-

-

0

Conversion of convertible preferred stock to common stock

-

-

-

3

0

27,324

0

-

0

Contingent success fee liability for term loan

-

-

-

116

0

0

-

-

-

Acquisition of Equipois assets with common stock and contingent consideration liability

-

-

-

0

1,839

0

0

-

-

Acquisition of property and equipment with capital lease

-

-

-

0

166

0

0

-

23

Conversion of preferred stock warrants to common stock warrants

-

-

-

-

-

-

-

-

0

Transfer of warrant liability to equity

-

-

62

1,363

0

-

-

-

0

Vesting of early exercised stock options

-

-

-

-

-

-

5

-

13